Company intelligence / Profile preview
Shenzhen Hornetcorn Biotechnology Co., Ltd.
_not_specified_, _not_specified_, Chinahornetcorn.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company is developing cellular therapies for cancer and autoimmune diseases. Its lead programs use human umbilical cord-derived mesenchymal stem cells for rheumatoid arthritis, DC-CIK therapies for colorectal cancer and esophageal carcinoma, and DC–CTLs for non-small cell lung cancer. Clinical trials are ongoing or pending; no late-stage results reported as of now.[1][3]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Mesenchymal stem cells (MSC)Dendritic cell–activated cytokine-induced killer cells (DC-CIK)Dendritic cell–activated cytotoxic T lymphocytes (CTLs)[1][3]
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Shenzhen Hornetcorn Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Hornetcorn Biotechnology Co., Ltd..